Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Selection criteria for genetic assessment of patients with familial melanoma

In English

Författare

  • Sancy A. Leachman
  • John Carucci
  • Wendy Kohlmann
  • Kimberly C. Banks
  • Maryam M. Asgari
  • Wilma Bergman
  • Giovanna Bianchi-Scarra
  • Teresa Brentnall
  • Brigitte Bressac-de Paillerets
  • William Bruno
  • Clara Curiel-Lewandrowski
  • Femke A. de Snoo
  • Tadeusz Debniak
  • Marie-France Demierre
  • David Elder
  • Alisa M. Goldstein
  • Jane Grant-Kels
  • Allan C. Halpern
  • Christian Ingvar
  • Richard F. Kefford
  • Julie Lang
  • Rona M. MacKie
  • Graham J. Mann
  • Kurt Mueller
  • Julia Newton-Bishop
  • Håkan Olsson
  • Gloria M. Peterson
  • Susana Puig
  • Darrell Rigel
  • Susan M. Swetter
  • Margaret A. Tucker
  • Emanuel Yakobson
  • John A. Zitelli
  • Hensin Tsao
Visa allt

Summary, in English

Approximately 5% to 10% of melanoma may be hereditary in nature, and about 2% of melanoma can be specifically attributed to pathogenic germline mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A). To appropriately identify the small proportion of patients Who benefit most from referral to a genetics specialist for consideration of genetic testing for CDKN2A, We have reviewed available published studies of CDKN2A mutation analysis in cohorts with invasive, cutaneous melanoma and found variability in the rate of CDKN2A mutations based on geography, ethnicity, and the type of study and eligibility criteria used. Except in regions of high melanoma incidence, such as Australia, we found higher rates of CDKN2A positivity in individuals with 3 or more primary invasive melanomas and/or families with at least one invasive melanoma and two or more other diagnoses of invasive melanoma and/or pancreatic cancer among first- or second-degree relatives on the same side of the family. The Work summarized in this review should help identify individuals who are appropriate candidates for referral for genetic consultation and possible testing. (J Am Acad Dermatol 2009;61:677-84.)

Publiceringsår

2009

Språk

Engelska

Sidor

677-684

Publikation/Tidskrift/Serie

Journal of American Academy of Dermatology

Volym

61

Issue

4

Dokumenttyp

Artikel i tidskrift

Förlag

Elsevier

Ämne

  • Dermatology and Venereal Diseases

Nyckelord

  • genetic testing
  • genetic counseling
  • CDKN2A
  • familial
  • hereditary
  • melanoma
  • p16

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 0190-9622